Nicotine Treatment of Mild Cognitive Impairment (MCI)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-09-30

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this 12-month study is to determine whether nicotine, administered in the form of nicotine patches, can improve symptoms of memory loss in some people experiencing mild memory problems (referred to in this study as "mild cognitive impairment" or MCI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Memory Improvement Through Nicotine Dosing (MIND) Study

NCT02720445

Mild Cognitive Impairment

COMPLETED PHASE2

Effect of Nicotine on Brain Reward Pathways

NCT02346539

Depressive Disorder

COMPLETED PHASE1

Nicotine Withdrawal Symptoms and Smoking Relapse

NCT01511614

Nicotine Dependence

COMPLETED NA

Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence

NCT00916721

Smoking Cessation

COMPLETED PHASE3

Combination Nicotine Patch / Lorcaserin for Smoking Cessation

NCT02906644

Nicotine Dependence

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to determine whether nicotine can improve symptoms of memory loss in some people experiencing mild memory problems (referred to in this study as "mild cognitive impairment" or MCI). The study will last approximately 12 months and will be conducted at 3 clinical sites in the United States.

Recent studies have suggested that one of the causes of memory disorders may be a reduction in a particular chemical substance in the brain. This chemical substance, acetylcholine, is thought to act on certain brain cells in a specific way that helps us to remember and use memories as well as affect our mood. In MCI (and Alzheimer's disease), the level of acetylcholine may be changed, and this may impair brain functioning. Preliminary studies have suggested that short-term administration of nicotine appears to improve memory in patients with mild memory loss and early Alzheimer's disease. Nicotine imitates many of the actions of acetylcholine. By administering nicotine over a longer period of time to patients with MCI, this study could lead to a better understanding of whether nicotine can act to improve memory loss symptoms over the longer term and whether it can help delay the progression of memory loss symptoms. The amount of nicotine in each patch used in this study is the same level found in patches that are used in people who are trying to quit smoking.

This study will include up to twelve visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age-Related Memory Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo Group

Placebo for first six months of study; moved to open-label active nicotine for second six months

Group Type PLACEBO_COMPARATOR

Placebo transdermal patch

Intervention Type DRUG

placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks

Active Nicotine Group

Blinded active nicotine for first six months of study; open-label active nicotine for second six months

Group Type EXPERIMENTAL

Transdermal nicotine patch

Intervention Type DRUG

double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transdermal nicotine patch

double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week

Intervention Type DRUG

Placebo transdermal patch

placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nicotrol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 55+.
* Memory complaints and memory difficulties which are verified by an informant.
* Abnormal memory function documented by scoring below the education adjusted cutoff on the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale - Revised (the maximum score is 25):

1. less than or equal to 8 for 16 or more years of education,
2. less than or equal to 4 for 8 - 15 years of education,
3. less than or equal to 2 for 0 - 7 years of education.
* Mini-Mental Status Exam score between 24 and 30 (inclusive).
* Clinical Dementia Rating of 0.5 with a memory box score of 0.5 or 1.0.
* General cognition and functional performance sufficiently preserved such that a diagnosis of Alzheimer's disease cannot be made by the site physician at the time of the screening visit.
* No significant cerebrovascular disease: Modified Hachinski score of less than or equal to 4.
* Stable medications for at least 1 month prior to screening.
* Hamilton Depression rating scale score of less than or equal to 12 on the 17-item scale.
* Informant is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more).
* Adequate visual and auditory acuity to allow neuropsychological testing.
* Good general health with no additional diseases expected to interfere with the study.
* Any conditions that subject may have must be stable for 3 months prior to screening.
* Participant is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile).
* Participants will be taking no drugs with pro- or anti-cholinergic properties.

Exclusion Criteria

* Any significant neurologic disease such as Alzheimer's disease, Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
* Major depression or another major psychiatric disorder as described in DSM-IV within the past 2 years.
* History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).
* Any significant, unstable medical condition.
* Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening.
* Any tobacco use within the past year.

Minimum Eligible Age

55 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No